Published in Exp Ther Med on June 14, 2017
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Regulation of the mevalonate pathway. Nature (1990) 18.25
Identification of the haemoglobin scavenger receptor. Nature (2001) 7.05
Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev (2006) 5.27
Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol (2005) 4.29
TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem (1997) 3.81
The molecular architecture of the TNF superfamily. Trends Biochem Sci (2002) 3.39
Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol (2000) 3.24
Mitochondrial dysfunction in atherosclerosis. Circ Res (2007) 3.09
The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem (1994) 3.07
Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 2.89
TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 2.69
Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res (2006) 2.68
Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine (2000) 2.18
A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 2.16
HMGB1 as a DNA-binding cytokine. J Leukoc Biol (2002) 2.07
TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev (2003) 1.96
TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem (1999) 1.93
Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol (2010) 1.88
TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine (2007) 1.87
A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol (1987) 1.86
TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem (2003) 1.81
Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol (1998) 1.75
The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 1.73
Soluble CD163. Scand J Clin Lab Invest (2011) 1.72
Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J (2010) 1.67
CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal (2012) 1.64
Regulation of CD 163 on human macrophages: cross-linking of CD163 induces signaling and activation. J Leukoc Biol (1999) 1.59
The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 1.59
Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol (2004) 1.57
Release of active tissue factor by human arterial smooth muscle cells. Circ Res (2000) 1.57
The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem (1999) 1.53
The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J (2003) 1.52
A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 1.52
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol (2009) 1.52
Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun (2002) 1.48
Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol (2002) 1.44
Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol (2012) 1.41
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb (1993) 1.38
Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci (2011) 1.37
Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int (2006) 1.34
TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J (2004) 1.33
HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol (2007) 1.31
Atherosclerosis as an inflammatory disease. Curr Pharm Des (2012) 1.31
Ber-MAC3: new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol (1991) 1.30
Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol (2008) 1.28
Hemoglobin and heme scavenger receptors. Antioxid Redox Signal (2010) 1.27
Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis (2006) 1.27
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.25
Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol (2006) 1.24
Immunocytochemical detection of Fcgamma receptors in human atherosclerotic lesions. Immunol Lett (2001) 1.21
TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun (2003) 1.21
Molecular characterization of the haptoglobin.hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem (2004) 1.20
Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis (2007) 1.18
Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies. Cold Spring Harb Perspect Med (2013) 1.18
Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake in vitro. Arterioscler Thromb Vasc Biol (2009) 1.18
Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost (1997) 1.18
Dual role for TWEAK in angiogenic regulation. J Cell Sci (2002) 1.16
Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br J Haematol (2002) 1.15
Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med (2005) 1.15
CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res (2009) 1.13
Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke (2006) 1.12
Intraplaque hemorrhage. Curr Mol Med (2006) 1.12
Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum (2004) 1.06
Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol (2005) 1.05
Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol (2010) 1.05
CD163 and its role in inflammation. Folia Histochem Cytobiol (2011) 1.04
Phenotypic and functional heterogeneity of porcine blood monocytes and its relation with maturation. Immunology (2005) 1.04
TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res (2010) 1.00
Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem (2009) 0.99
Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun (2003) 0.99
Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis (2011) 0.99
Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf) (2015) 0.97
Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J Biomed Res (2013) 0.96
Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One (2012) 0.95
TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci (2007) 0.93
Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. Immunobiology (2009) 0.93
Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract (2005) 0.92
Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One (2014) 0.90
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 0.89
TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. Front Immunol (2014) 0.87
HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol (2013) 0.86
The pathogenesis of atherosclerosis and new opportunities for treatment and prevention. J Neural Transm Suppl (2002) 0.86
Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res (1998) 0.85
High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther (2013) 0.84
Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol (2013) 0.83
Role of mast cells in atherosclerosis: a classical inflammatory disease. Int J Immunopathol Pharmacol (2015) 0.82
Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. J Cell Mol Med (2014) 0.81
Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application. Front Physiol (2014) 0.81
Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. Proteomics Clin Appl (2011) 0.79
Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. Cytokine (2014) 0.79
TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovasc Res (2015) 0.78
Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease. Int J Clin Exp Med (2015) 0.76